(+)-(2R)-4-azidobutane-1,2-diol | 872104-51-3

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: (+)-(2R)-4-azidobutane-1,2-diol
• 英文别名: (2R)-4-azidobutane-1,2-diol
• CAS: 872104-51-3
• 化学式: C₄H₉N₃O₂
• 分子量: 131.134
• InChiKey: CBRREUPPRHQWCX-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+)-(2R)-4-azidobutane-1,2-diol 在 咪唑 、 叔丁基二甲基氯硅烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 2-Butanol, 4-azido-1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, (2R)-
  参考文献：
  名称：

  Ester derivatives

  摘要：

  这项发明涉及表现出选择性肌肉M3受体拮抗作用、副作用小、适用于吸入疗法并且可用作治疗呼吸系统疾病的治疗剂的化合物，其一般式为（I）； 其中A表示由式（a0）或（b0）表示的基团； Ar表示可选择取代的芳基或杂环芳基；B1和B2表示脂肪烃基；R1表示氟取代的环烷基；R2、R3和R4表示较低的烷基、与B1结合的单键或烷基，或者R2和R3结合表示烷基；R5和R7表示氢、较低的烷基，或者与B2结合的单键或烷基；R6表示氢、较低的烷基或表示为—N(R8)R9的基团；X-表示阴离子。

  公开号：

  US20030191316A1
• 作为产物：
  描述：

  (4R)-4-(2-azidoethyl)-2-tert-butyl-1,3-dioxolane 在 Amberlyst 15 acidic form 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以100%的产率得到(+)-(2R)-4-azidobutane-1,2-diol
  参考文献：
  名称：

  Structure–affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol

  摘要：

  The synthesis and NMDA receptor affinity of ring and side-chain homologues of etoxadrol and dexoxadrol are described. For the regioselective synthesis of etoxadrol homologues, the regioisomeric 4-azidobutanediols (+/-)-9 and (+/-)-14 were employed. A synthesis of the enantiomerically pure azidobutanediols (S)-, (R)-9 and (S)-, (R)-14 was developed and the homochiral building blocks were used for the synthesis of enantiomerically pure etoxadrol and dexoxadrol homologues. The affinity of the racemic and enantiomerically pure primary amines toward the phencyclidine binding site of the NMDA receptor was investigated in receptor binding studies with tritium labeled [H-3]-(+)-MK-801 as radioligand. Benzaldehyde derivatives (+/-)-12a, (+/-)-13a, and (+/-)-16a bearing a proton at the acetalic position do not interact significantly with the NMDA receptor. An enantioselective NMDA receptor binding was observed for the trans-configured 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl)ethanamine 13b, the (2-ethyl-2-phenyl-1,3-dioxan-4-yl)methanamine 16b, and the (2,2-diphenyl-1,3-dioxan-4-yl)methanamine 16c. The NMDA receptor affinity of these compounds resides almost exclusively in the (S)-configured enantiomers (2S,4S)-13b, (2S,4S)-16b, and (4S)-16c. The lowest K-i-value in this series was found for the (2S,4S)-configured 1,3-dioxolane (2S,4S)-13b (K-i = 69 nM), which is in the range of the Ki-value of the lead compounds etoxadrol and dexoxadrol, indicating that the 2-aminoethyl and the piperidin-2-yl substituents lead to similar NMDA receptor interactions. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.030

文献信息

• Imidazothiazole derivatives
  申请人：Kawato Haruko

  公开号：US20090312310A1

  公开（公告）日：2009-12-17

  There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , and R 5 in the formula (1) each has the same meaning as defined in the specification.

  提供了一种新的化合物，它抑制小鼠双分子分钟2（Mdm2）蛋白与p53蛋白之间的相互作用，并展现出抗肿瘤活性。本发明提供了一种咪唑噻唑衍生物，其表示为以下公式（1），具有各种取代基，可抑制Mdm2蛋白与p53蛋白之间的相互作用并展现出抗肿瘤活性：其中，公式（1）中的R1、R2、R3、R4和R5每个都具有规范中定义的相同含义。
• Ester derivatives
  申请人：——

  公开号：US20030191316A1

  公开（公告）日：2003-10-09

  This invention relates to compounds which exhibit selective muscarinic M 3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); 1 [in which A signifies a group expressed by a formula (a 0 ) or (b 0 ); 2 Ar signifies optionally substituted aryl or heteroaryl; B 1 and B 2 signify aliphatic hydrocarbon; R 1 signifies fluorine-substituted cycloalkyl; R 2 , R 3 and R 4 signify lower alkyl, single bond or alkylene bonded to B 1 , or R 2 and R 3 are united to signify alkylene; R 5 and R 7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B 2 ; R 6 signifies hydrogen, lower alkyl or a group expressed as —N(R 8 )R 9 ; and X − signifies an anion].

  这项发明涉及表现出选择性肌肉M3受体拮抗作用、副作用小、适用于吸入疗法并且可用作治疗呼吸系统疾病的治疗剂的化合物，其一般式为（I）； 其中A表示由式（a0）或（b0）表示的基团； Ar表示可选择取代的芳基或杂环芳基；B1和B2表示脂肪烃基；R1表示氟取代的环烷基；R2、R3和R4表示较低的烷基、与B1结合的单键或烷基，或者R2和R3结合表示烷基；R5和R7表示氢、较低的烷基，或者与B2结合的单键或烷基；R6表示氢、较低的烷基或表示为—N(R8)R9的基团；X-表示阴离子。
• Structure–affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol
  作者：Marion Aepkers、Bernhard Wünsch

  DOI：10.1016/j.bmc.2005.07.030

  日期：2005.12

  The synthesis and NMDA receptor affinity of ring and side-chain homologues of etoxadrol and dexoxadrol are described. For the regioselective synthesis of etoxadrol homologues, the regioisomeric 4-azidobutanediols (+/-)-9 and (+/-)-14 were employed. A synthesis of the enantiomerically pure azidobutanediols (S)-, (R)-9 and (S)-, (R)-14 was developed and the homochiral building blocks were used for the synthesis of enantiomerically pure etoxadrol and dexoxadrol homologues. The affinity of the racemic and enantiomerically pure primary amines toward the phencyclidine binding site of the NMDA receptor was investigated in receptor binding studies with tritium labeled [H-3]-(+)-MK-801 as radioligand. Benzaldehyde derivatives (+/-)-12a, (+/-)-13a, and (+/-)-16a bearing a proton at the acetalic position do not interact significantly with the NMDA receptor. An enantioselective NMDA receptor binding was observed for the trans-configured 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl)ethanamine 13b, the (2-ethyl-2-phenyl-1,3-dioxan-4-yl)methanamine 16b, and the (2,2-diphenyl-1,3-dioxan-4-yl)methanamine 16c. The NMDA receptor affinity of these compounds resides almost exclusively in the (S)-configured enantiomers (2S,4S)-13b, (2S,4S)-16b, and (4S)-16c. The lowest K-i-value in this series was found for the (2S,4S)-configured 1,3-dioxolane (2S,4S)-13b (K-i = 69 nM), which is in the range of the Ki-value of the lead compounds etoxadrol and dexoxadrol, indicating that the 2-aminoethyl and the piperidin-2-yl substituents lead to similar NMDA receptor interactions. (c) 2005 Elsevier Ltd. All rights reserved.